BLUE BIOFUELS, INC.
Blue Biofuels develops renewable-energy and biofuel technologies, including its patented Cellulose-to-Sugar (CTS) process. CTS uses mechanical and chemical steps to break down cellulosic materials, such as grasses and agricultural waste, into fermentable sugars for conversion to biofuels. The company also licenses Vertimass technology, which converts ethanol into sustainable aviation fuel and other renewable fuels, including bio-gasoline. Blue Biofuels makes money through its biofuel technologies and plans to produce fuels and earn renewable-fuel credits when its facilities enter commercial operation. The company formed VertiBlue Fuels, LLC, a 50-50 joint venture with Vertimass, to develop an ethanol-to-sustainable-aviation-fuel facility in Florida. Blue Biofuels completed a pilot plant in 2023 and finalized pilot-scale testing and optimization in 2025. It is headquartered in Palm Beach Gardens, Florida.
Blue Biofuels reported no revenue and a net loss of $1.39M for 3Q 2026, widening from a loss of $422.55K in the prior-year quarter. The increase in loss was driven by higher equity-based compensation in R&D and G&A expenses. The company is seeking funding for its demonstration units and commercial facilities.
Bucharest Stock Exchange closed higher on Thursday. Total transaction value neared 1.5 billion lei. The BET index rose 2.37% to 35,027.65 points. Trading focused on Banca Transilvania (about 38m lei), Digi (30.3m) and Romgaz (29m). The voluntary takeover offer for Biofarm by Zaklady Farmaceutyczne Polpharma closed during the session.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BIOF (BLUE BIOFUELS, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent BIOF coverage spans earnings and mergers & acquisitions.
In the last 30 days, BIOF insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($60K). The most active reporter was Kneppers Chris J with 4 filings.
The company posted a larger quarterly loss and higher expenses, indicating deteriorating financial health.
Takeover-offer closing is the key event tied to Biofarm, likely affecting deal completion expectations and near-term liquidity.
AlphAI scores every news story that mentions BIOF with an AI model for sentiment and relevance, and aggregates insider trades from BLUE BIOFUELS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Blue Biofuels reported no revenue and a net loss of $1.39M for 3Q 2026, widening from a loss of $422.55K in the prior-year quarter. The increase in loss was driven by higher equity-based compensation in R&D and G&A expenses. The company is seeking funding for its demonstration units and commercial facilities.
Bucharest Stock Exchange closed higher on Thursday. Total transaction value neared 1.5 billion lei. The BET index rose 2.37% to 35,027.65 points. Trading focused on Banca Transilvania (about 38m lei), Digi (30.3m) and Romgaz (29m). The voluntary takeover offer for Biofarm by Zaklady Farmaceutyczne Polpharma closed during the session.
